Rare disease landscaping

Rare disease landscaping, also called rare disease landscape analysis, is the mapping of the clinical, stakeholder and policy environment around a rare disease. It shows how the field actually behaves, so strategy is built on real conditions rather than assumptions.

Market research measures attitudes and tracks competitors. Rare disease landscaping maps the whole system that decides adoption: standard of care, referral patterns, payers, policy, and the people who shape each. It explains why a product will be carried or blocked, not only what people currently think.

As early as possible. The most value comes before positioning and evidence plans are fixed, when the findings can still change your strategy. Bringing us in early is cheaper than correcting course after launch.

We work across therapy areas, with particular depth in rare disease and specialty conditions, where the stakeholder system is complex and the standard of care is contested.

We focus on European markets, where healthcare systems are fragmented and decisions differ by country. We can extend the analysis to other regions on request.

Through direct, structured engagement with clinicians, payers, policy actors and patient voices in each market. We design the conversations to surface how they actually frame the disease and the alternatives, not what they think they should say. This perception layer is the differentiating signal we bring into the landscape.

A living map of the disease ecosystem, named stakeholders by role, a documented perception view per stakeholder group, and a written report with clear implications for your scientific, access and commercial strategy.

Yes. Our disease landscaping consultancy runs as a standalone engagement or as the first step of a wider rare disease consulting programme. Most teams start with a rare disease landscape analysis and then add barrier and driver analysis or TPP validation on top of the same baseline.

Scope and timing are agreed around your research question, priority markets and stakeholder groups. A focused engagement across two to three European markets typically runs six to ten weeks, and we confirm the fee before any work starts. Where you want the landscape kept current, we agree updates twice per year, or sooner when important developments affect your programme.

We developed Mappiq, our own KOL tracker that uses an AI-powered synthesis of literature, trial, conference, guideline, and digital data to show you who actually leads a rare disease field: the specialists who treat, research, refer and decide, mapped as one picture. Mappiq matches the KOLs with the relevance to your programme, so not a standard database of experts with no relevance to your programme.